India: Are Known Substances Really A Patentable Subject Matter In Light Of Indian Patents Act, 1970

Last Updated: 1 March 2016
Article by Aayush Sharma

Most Read Contributor in India, September 2016


It is well stated in the Indian Patents Act, 1970 that grant of Product patent in India mainly in the areas of Pharmaceutical industry holds a relevance importance. In the last Patents (Amendment) Act, 2005 which is deemed to be revolutionized patent regime in India, amendment incorporated the provision of granting product patents in India. With the commencement of the amendment Act, patent protection in the fields of food, pharma, and drug products is now readily possible. The Indian patent practice relating to the patenting of food, medicine and drug products or biological material is relatively new and thus not so well established. Considering all patenting issues after the 2005 amendment, one of the major issue of this new regime is whether the discovery of a new use of a known substance or pharmaceutical composition would be entitled to a patent protection or not. Now with this article we discuss the issue of patentability of a new or subsequent medical use of a compound or composition wherein the first medical use of same is already known.

From the Indian Perceptive:

With the execution of Indian Patents (Amendment) Act, 2005, it is now possible to obtain patent protection on a substance intended to be used or capable of being used as a medicine or drug. According to section 3 (d) of the Act, "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant."1

Moreover, to obtain a patent for the second and subsequent use of a medicament the therapeutic efficacy must be enhanced or at least a new reactant must be employed in its manufacture. Section 3(d) clearly indicates that a substance or a composition must be novel, should involve an inventive step and should be capable of industrial application, whereas, swiss-type claim format deviates from the rule of absolute novelty. The discovery of previously unrecognized useful property of a drug is not considered novel in India and hence is not patentable. This section of the act makes it clear that swiss-type claims are not accepted for patent protection in India. An improvement made to a known substance does not qualify for patent protection in India.

The Act considers salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance to be the same substance, unless they differ significantly in properties with regard to efficacy. In India only a new chemical entity or a new molecule entity is granted protection. Formulations, such as, combinations of pharmaceuticals, changes in dosage form, new use of a known medicament, etc, are considered not patentable as there is lack of inventive step.

The Scope of Patentability of New Use of a Known Substance or Composition- From US and EPO perceptive

There are different opinions regarding patentability of second and subsequent medical uses of known substances or pharmaceutical compositions. Under the Patent Laws of various countries, discovery of a new advantage of a known substance or pharmaceutical composition is considered as a new invention that qualifies to be patentable.

As per United States Patents Law US Code 101 "whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title."2 The claims addressed at the method of treatment are accepted in US, therefore it alleviates the need of swiss-type claim format. However US patent and Trademark Office (USPTO) accepts swiss-type claims.

According to Section 4A (3) of the United Kingdom (UK) Patents Act 1977 (as amended), "in the case of an invention consisting of a substance or composition for use in any such method, the fact that the substance or composition forms part of the state of the art shall not prevent the invention from being taken to be new if the use of the substance or composition in any such method does not form part of the state of the art."3 That is to say, the UK Patents Act regarded discovery of a new purpose of a known drug to be novel. The second and subsequent use of a known drug was not considered as lacking in novelty if the subsequent use did not form a part of the state-ofthe- art. In Wyeth's Application [1985] RPC 545, one of the claims was drafted in the swiss-type format for patenting a new therapeutic use of a known drug which was refused by the examiner and later permitted by the UK Patents court on an appeal.

In a post G2/08 practice note issued by the UK Intellectual Property Office (IPO) the swiss-type claim format was prohibited from use in any UK patent application without any equivalent "grace period". Moreover, from the issuance of G2/08 the swisstype claim format claiming second or subsequent medical use of a known drug was objected to by the UK IPO on the ground of lack of clarity.

Use of swiss type Claim method:-

Swiss type claims The origin of 'swiss-type claim format' is supported by the fact that the 'discovery of new use of a known drug' by a pharmaceutical company employs time, money and labor which makes the 'new use' equally worthy of patent protection as compared to the original research which established the first pharmaceutical use of that drug. To tackle the issue of establishing the 'Novelty of Purpose,' the European Patent Office and the Swiss Patent Office adopted the swiss-type claim format. The use of this form of claim format is derogation from the obligation for absolute novelty. Its format is "Use of substance X in the preparation of a medicament for the treatment of disease Y."

The reasons for exclusion

The basis for the exclusion of 'new use of already known chemical entity' from patentability is that it might lead to ever greening of that chemical entity. Through ever greening companies try to secure patents on large numbers of complex and often highly speculative patents through minor modifications, when the original patent over the active compound of a brand-name drug is due to expire. These subsequent patents cover different forms of the substance or minor variation and everything from aspects of the manufacturing process to tablet color, or even a chemical produced by the body when the drug is ingested and metabolized by the patient.

By ever greening the multinational pharmaceutical companies are retaining profits from their blockbuster drugs for long as possible. Pharmaceutical giants in countries like US adopt the swiss-type claim format as a monopolization strategy to evergreen their patented drugs.


It is clear from the Indian Patents Act, 1970, which mandates that for being patentable a substance or a composition must be novel, should involve an inventive step and should be capable of industrial application, whereas, swiss-type claim format deviates from the rule of absolute novelty. As per s. 3(d) of the Act, to obtain a patent for the second and subsequent use of a medicament, the therapeutic efficacy must be enhanced or at least a new reactant must be employed in its manufacture.

The stringent approach of Indian patent law towards the exclusion of swiss-type claim format has made the pharmaceutical industries reluctant towards further improvement of a known drug or discovery of new therapeutic use of a known substance. It is clear from the above paragraphs and discussions, that pharmaceutical research does not halt on patenting of one pharmaceutical activity mainly due to ongoing research the same drug may be found to have other beneficial properties which was previously unrecognized. Therefore, from the viewpoint of a pharma industry the exemption of swiss-type claim format in India is unwelcoming and would rather harm to the Industry.





The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.